Immunodeficiency UK has launched a new national survey exploring the experiences of patients, carers, and healthcare professionals who have been affected by changes to immunoglobulin (IG) therapy.
Switches between IG products or delivery methods can happen for many reasons, from clinical needs or supply issues to NHS procurement updates. But these changes can have a real impact on patients' independence, confidence, and quality of life, as well as on the healthcare professionals who support them.
For patients and carers: share your experience
If you receive immunoglobulin therapy — or care for someone who does — we want to hear from you.
The patient survey explores:
- Whether and how often patients were switched
- Who initiated the switch
- Why the switch occurred
- Whether patients were informed or involved
- Nature of the change (brand/mode/setting)
- Impact on independence, cost, mental health
- Satisfaction of switching
Even if you haven't yet been switched but have been told a change is coming, your views are important. Your feedback will help strengthen our advocacy for better communication, patient choice, and continuity of care.
Take the patient survey here: https://form.typeform.com/to/tOLBLzMJ
For healthcare professionals: your perspective counts
We are also inviting healthcare professionals to share their insights through a dedicated survey, designed to capture the professional experience of managing IG therapy switches.
This survey can be found at https://www.immunodeficiencyuk.org/resources/for-professionals/behind-the-ig-therapy-switch-healthcare-professional-experiences.
October 2025
